Ascenion has mediated a license agreement between the Helmholtz Zentrum München and ITM Isotopen Technologien München AG providing the company with exclusive rights to monoclonal antibodies targeting mutant forms of E-cadherin. These forms, D8- and D9-cadherin, are only present on certain gastric cancer cells, but not on healthy tissues. ITM, a leading developer of radioisotope therapies and integrated application systems, plans to conjugate the antibodies to certain radioisotopes (Alpha- and Betaemitting) and develop them for specific gastric cancer treatment. The Helmholtz Zentrum München receives license fees and is eligible to royalties on potential sales.


For further information please contact: This e-mail address is being protected from spambots. You need JavaScript enabled to view it